Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of neoadjuvant atezolizumab plus platinum chemotherapy in resectable non-small cell lung cancer
MOH_2018-05-10_002335Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Planned start May 2018; status: not yet recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2018-05-10_002335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-10_002335.